Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study

Fabian Trillsch, Sven Mahner, Beyhan Ataseven, Rebecca Asher, Nanda Aryal, Coraline Dubot, Andrew Clamp, Richard T. Penson, Amit Oza, Amnon Amit, Tomasz Huzarski, Antonio Casado, Giovanni Scambia, Michael Friedlander, Nicoletta Colombo, Keiichi Fujiwara, Gabe S. Sonke, Hannelore Denys, Elizabeth S. Lowe, Chee K. LeeEric Pujade-Lauraine

Dipartimento di Scienze della vita e sanità pubblica
Facoltà di Medicina e Chirurgia "A.Gemelli"
Ambito disciplinare: Clinica Ginecologica

Ludwig Maximilian University of Munich
University of Sydney
Institut Curie
The Christie NHS Foundation Trust
Department of Molecular Biology
Princess Margaret Cancer Centre
Technion-Israel Institute of Technology
Pomeranian Medical University in Szczecin
Hospital Clínico San Carlos de Madrid
University of New South Wales
University of Milan - Bicocca
Saitama Medical University
Netherlands Cancer Institute
Ghent University
AstraZeneca
Université de Paris

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Ordina per
Peso
Alfabetico

Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study

Fingerprint

Medicine and Dentistry